Headquartered in Baltimore, MD, Lupin Pharmaceuticals, Inc. (LPI) is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across US & Europe. Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited.
Founded by Ms. Vinita Gupta, LPI commenced business operations in 2005 with the launch of its flagship brand Suprax. LPI did not adopt the traditional Generics & API route that a majority of other peers had adopted till then to address the American Market. Seven years hence, LPI remains one of the few Generics Pharma Majors with a substantial brands business in the US. The flagship brand Suprax today, has sales upwards of 70 million USD.
LPI also entered the American Generics pharmaceuticals market within a year of launching Suprax. The strategy was to bring meaningful, differentiated niche products in keeping with Lupin's research, intellectual property management & manufacturing strengths. Over the last few years, LPI has built one of the most quality generic product pipelines for the US market addressing a Market opportunity valued at over USD 30 billion.
In just 7 years of having commenced business operations, LPI today is the 5th largest and the fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health).
The Companyís business in the US and Europe recorded another year of strong performance with total sales of INR 22,017 million during FY 2011, up from INR 17,893 million during the previous fiscal, registering a growth of 23%. Lupin also further strengthened its European business where the company reported revenues of USD 41 million for FY 2011, up from USD 28 million during FY 2010 registering a growth of 44%.
Formulations sales in the US market grew to INR 20,080 million during FY 2011, up from INR 16,542 million during the previous year, a growth of 21 %. The Brands Business contributed 30% to the total US sales and Generics business contributed 70% during FY 2011.
US and Europe maintain pole position in terms of being the principal growth engine for the Company, and are the major contributors to Lupin revenues and margins. Our philosophy is to ceaselessly explore the full potential of Lupinís opportunities in these geographies. Current plans include an expansion of our generic portfolio, introduction of new brands, increasing the geographic footprint in Europe and preparing for an entry into the Canadian marketplace. In addition, we will continue to improve on our current market shares to enhance margins further. That is Being Lupin; a relentless quest to push the boundaries of conventional business thinking to seek optimization and differentiation in every aspect of our business.
For more information log on to www.lupinpharmaceuticals.com